Luspatercept for lower red blood counts in MDS with del5q
Treatments studied
Part of Blood & lymphatic clinical trials.
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign consent before any study testing.
- You have MDS with del5q (a specific chromosome change), and your risk level is very low, low, or intermediate, with low blast cells in the bone marrow.
- Your anemia has not responded to (or you could not tolerate) ESA medicines, and treatment may be stopped at least 4 weeks before screening.
- You have tried or cannot take lenalidomide (or could not tolerate it), with specific timing and blood-count limits, and you have been getting regular red blood cell transfusions for at least 16 weeks.
- Your body is able to handle treatment: performance status is 0–2, and your kidney, liver, and bilirubin blood tests meet limits.
- You meet pregnancy/sex protection rules (for everyone who can become pregnant or for partners during sex) and you can follow the visit schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether luspatercept can improve anemia in people with lower-risk myelodysplastic syndrome (MDS) who do not currently need red-blood-cell transfusions. It’s also looking to see if the benefit is similar whether or not you have ring sideroblasts.
This Phase 1/2 study tests luspatercept combined with another approach in people with low-risk myelodysplastic syndrome (MDS) who are not responding to or cannot use ESA (a common anemia treatment). It may help improve anemia (low hemoglobin), reduce transfusions, and control the disease if you fit the specific criteria.
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
This trial tests a drug called luspatercept for people with a condition called CCUS, where they have low blood counts and a gene change. The goal is to see if the drug can improve blood counts and reduce symptoms like fatigue or bleeding risk.
This trial tests elritercept, a medicine meant to improve anemia (low blood count) in adults with certain lower-risk bone marrow disorders called MDS. If you qualify, the study may help reduce the need for blood transfusions or improve anemia symptoms.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.